{"id":"cl-108","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CL-108 works by targeting and inhibiting the TRPM8 receptor, which is involved in the transmission of pain signals. This inhibition leads to a reduction in pain perception without the side effects associated with traditional opioids.","oneSentence":"CL-108 is a novel, orally administered, non-opioid, non-sedating, and non-addictive analgesic.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:13.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain"},{"name":"Chronic pain"}]},"trialDetails":[{"nctId":"NCT07153172","phase":"PHASE1","title":"Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-06","conditions":"Obesity","enrollment":91},{"nctId":"NCT03657810","phase":"PHASE3","title":"A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV","status":"COMPLETED","sponsor":"Charleston Laboratories, Inc","startDate":"2017-08-02","conditions":"Pain, Nausea, Vomiting","enrollment":349},{"nctId":"NCT02712554","phase":"PHASE1","title":"A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route","status":"COMPLETED","sponsor":"Charleston Laboratories, Inc","startDate":"2015-06","conditions":"Pain, Nausea, Vomiting","enrollment":40},{"nctId":"NCT02465866","phase":"PHASE1","title":"A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions","status":"COMPLETED","sponsor":"Charleston Laboratories, Inc","startDate":"2014-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT02462850","phase":"PHASE3","title":"A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip","status":"COMPLETED","sponsor":"Charleston Laboratories, Inc","startDate":"2014-10","conditions":"Pain, Nausea, Vomiting","enrollment":178},{"nctId":"NCT01780428","phase":"PHASE3","title":"Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain","status":"COMPLETED","sponsor":"Charleston Laboratories, Inc","startDate":"2013-01","conditions":"Pain, Nausea, Vomiting","enrollment":460},{"nctId":"NCT02462811","phase":"PHASE3","title":"A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)","status":"COMPLETED","sponsor":"Joseph Hazelton","startDate":"2014-09","conditions":"Pain, Nausea, Vomiting","enrollment":552}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low-dose CL-108 and High-dose CL-108"],"phase":"phase_3","status":"active","brandName":"CL-108","genericName":"CL-108","companyName":"Charleston Laboratories, Inc","companyId":"charleston-laboratories-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CL-108 is a novel, orally administered, non-opioid, non-sedating, and non-addictive analgesic. Used for Acute pain, Chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}